Pipeline

Our Innovative Project Pipeline

An innovative therapeutic pipeline aiming disease modifying principles for successfully treating human diseases. Our programs have identified new small molecules active in key biological targets involved in severe metabolic and neurological diseases.

Our current pipeline progress successfully towards the development of new medicinal principles for the treatment of Obesity, Parkinson’s disease and Epilepsy.

Projects in pipeline :

4

ABXY-1

Hit-to-Lead

ABXY-1002

Hit-to-Lead

ABXY-3

Advanced Lead Optimization

ABXY-5

Hit-Identification

Next generation of medicines for Obesity and Metabolic disorders

Our pipeline combines innovative Early Discovery and Advanced Preclinical programs aiming the treatment of Obesity and Metabolic Disorders.

ABXY-3 lead program aims to complete regulatory data package for a severe Obesity orphan indication. ABXY-3 program Lead candidate is an oral efficacious positive allosteric modulator of GLP-1 receptor with a very competitive preclinical profile

Aiming to provide innovation for the treatment of metabolic disorders, program ABXY-5 identified a key new mechanism for the control of GLP-1 metabolic pathway. The program aims to develop modulators for a non-disclosed druggable target for the treatment of Obesity.

looking ahead to future neurotherapeutics